Global Neurostimulation Devices Market 2015 is a new market research publication announced by Reportstack. Available pharmacological treatment for conditions such as chronic pain, epilepsy, Parkinson’s disease, and depression are not sufficient for all patients at all stages of treatment. More than 100 million people suffer from these conditions in the US alone. Though drug therapy, physiotherapy, and surgeries are effective treatment options, they are not suitable for all patients. For example, approximately 15-20% of epilepsy patients are drug-resistant and require alternate treatment method. Neurostimulation is a potential alternative for patients for whom the drug therapy or surgery is not effective.Neurostimulation devices are implantable devices that help in the therapeutic activation of the nervous systems. These devices deliver electrical stimulation to the brain and nervous systems for the treatment of various types of neurological disorders such as pain, epilepsy, Parkinson's disease, depression, obsessive-compulsive disorder, dystonia, and tremors. These devices target specific areas of the brain or spinal cord by blocking the pain messages before they reach the brain. The analysts forecast that the global neurostimulation devices market to grow at a CAGR of 5.37% over the period 2014-2019.

To access full report with TOC, please visit  Global Neurostimulation Devices Market 2015.

Covered in this ReportThe report covers the present scenario and the growth prospects of the global neurostimulation devices market for the period 2015-2019. Based on devises, the market can be segmented into the following: SCS systems, DBS systems, SNS systems, VNS systems, and others.The report, Global Neurostimulation Devices Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and APAC and EMEA; it also covers the global neurostimulation devices market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.Key Regions• Americas • APAC• EMEA Key Vendors• Boston Scientific • Cyberonics • Medtronic • St. Jude Medical Other Prominent Vendors

• Aleva Neurotherapeutics• Atrotech• Autonomic Technologies• ElectroCore• Endostim• EnteroMedics• ImThera Medical• Inspire Medical Systems• Neuros Medical• NeuroMetrix• NeuroPace• NeuroSigma• Nevro• SPR Therapeutics• Synapse BiomedicalMarket Driver• Rise in Prevalence of Neurological Disorders• For a full, detailed list, view our reportMarket Challenge• Not First Line of Treatment Therapy • For a full, detailed list, view our reportMarket Trend• Significant Increase in Product Development and Launches • For a full, detailed list, view our reportKey Questions Answered in this Report• What will the market size be in 2018 and what will the growth rate be?• What are the key market trends?• What is driving this market?• What are the challenges to market growth?• Who are the key vendors in this market space?• What are the market opportunities and threats faced by the key vendors?• What are the strengths and weaknesses of the key vendors?

Companies Mentioned

Boston Scientific, Cyberonics, Medtronic, St. Jude Medical, Aleva Neurotherapeutics, Atrotech, Autonomic Technologies, ElectroCore, Endostim, EnteroMedics, ImThera Medical, Inspire Medical Systems, Neuros Medical, NeuroMetrix, NeuroPace, NeuroSigma, Nevro, SPR Therapeutics, Synapse Biomedical

Contact:

Debora WhiteManager - Marketing debora@reportstack.comPh: +1-888-789-6604Reportstack Market Research###